|Videos|November 18, 2020

Overlapping diseases and COVID-19's impact

Author(s)Brooke Henson, Editor, Tracy Schroeder Swartz, OD, MS, FAAO, Marguerite McDonald, MD

Episodes in this series

EP. 1 Introduction and overview

EP. 1 Introduction and overview

EP. 2 Consequences and epidemiology of untreated dry eye

EP. 2 Consequences and epidemiology of untreated dry eye

EP. 3 Diagnosis and overlooking asymptomatic patients with DED

EP. 3 Diagnosis and overlooking asymptomatic patients with DED

EP. 4 Standard testing and assessment for DED

EP. 4 Standard testing and assessment for DED

EP. 5 General Principles of Treatment of DED

EP. 5 General Principles of Treatment of DED

EP. 6 OD and MD communication for optimal care

EP. 6 OD and MD communication for optimal care

EP. 7 Review of artificial tears for DED

EP. 7 Review of artificial tears for DED

EP. 8 Corticosteroids and Immunomodulators for the treatment of dry eye

EP. 8 Corticosteroids and Immunomodulators for the treatment of dry eye

Eric Donnenfeld, MD, and Marguerite McDonald, MD, discuss the role of nutritional supplements as well as antibiotics in dry eye management.

EP. 9 The role of nutritional supplements and antibiotics in DED

Crystal Brimer, OD, FAAO, identifies the preferred treatment options for meibomian gland dysfunction.

EP. 10 How to treat meibomian gland dysfunction

Crystal Brimer, OD, FAAO, shares some in-office procedures for dry eye and the patient resistance with high cost.

EP. 11 In-office procedures and patient resistance for DED treatments

EP. 12 Treatments for aqueous dry eye

EP. 12 Treatments for aqueous dry eye

EP. 13 Challenges in the management of DED

EP. 13 Challenges in the management of DED

EP. 14 Counseling and formulary concerns for DED therapies

EP. 14 Counseling and formulary concerns for DED therapies

EP. 15 Overlapping diseases and COVID-19's impact

EP. 15 Overlapping diseases and COVID-19's impact

EP. 16 Agents in the pipeline for DED

EP. 16 Agents in the pipeline for DED

EP. 17 Novel agents in the pipeline for DED

EP. 17 Novel agents in the pipeline for DED

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Related to this article

From Paper to Clinic, Episode 8: Dynamic Muscle Stimulation and the Blink Physiology Behind Dry Eye

October 5th, 2026

From Paper to Clinic, Episode 8: Dynamic muscle stimulation and the blink physiology behind dry eye

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

More than monitoring: Using AMD visits to promote healthy vision aging

FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours

Brepocitinib for noninfectious uveitis meets all phase 3 trial end points

BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial

Study: OCTA analysis tools report different macular vessel density values for glaucoma